Abstract
The oceans are a source of a large group of structurally unique natural products that are mainly found in invertebrates such as sponges, tunicates, bryozoans, and molluscs. It is interesting to note that the majority of marine compounds currently in clinical trials or under preclinical evaluation are produced by these species rather than as secondary metabolites by marine algae [1]. Through the combined efforts of marine natural products chemists and pharmacologists a number of promising compounds have been identified that are either already at advanced stages of clinical trials such as the new anti-cancer drug marine alkaloid ecteinascidin 743 [2], or have been selected as promising candidates for extended preclinical evaluation [3]. This is the case for conotoxins, (Table 1) where a number of conopeptides are currently being developed as analgesics for the treatment of neuropathic pain.
Keywords: neuropathic pain, antidepressant, new antidepressant drugs, antinociception, mechanism of action, clinical trials
Mini-Reviews in Medicinal Chemistry
Title: Drugs From the Sea: Conotoxins as Drug Leads for Neuropathic Pain and Other Neurological Conditions
Volume: 3 Issue: 7
Author(s): D. Alonso, Z. Khalil, N. Satkunanthan and B. G. Livett
Affiliation:
Keywords: neuropathic pain, antidepressant, new antidepressant drugs, antinociception, mechanism of action, clinical trials
Abstract: The oceans are a source of a large group of structurally unique natural products that are mainly found in invertebrates such as sponges, tunicates, bryozoans, and molluscs. It is interesting to note that the majority of marine compounds currently in clinical trials or under preclinical evaluation are produced by these species rather than as secondary metabolites by marine algae [1]. Through the combined efforts of marine natural products chemists and pharmacologists a number of promising compounds have been identified that are either already at advanced stages of clinical trials such as the new anti-cancer drug marine alkaloid ecteinascidin 743 [2], or have been selected as promising candidates for extended preclinical evaluation [3]. This is the case for conotoxins, (Table 1) where a number of conopeptides are currently being developed as analgesics for the treatment of neuropathic pain.
Export Options
About this article
Cite this article as:
Alonso D., Khalil Z., Satkunanthan N. and Livett G. B., Drugs From the Sea: Conotoxins as Drug Leads for Neuropathic Pain and Other Neurological Conditions, Mini-Reviews in Medicinal Chemistry 2003; 3 (7) . https://dx.doi.org/10.2174/1389557033487746
DOI https://dx.doi.org/10.2174/1389557033487746 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Transglutaminases - Possible Drug Targets in Human Diseases
Current Drug Targets - CNS & Neurological Disorders Microemulsions as Carriers for Therapeutic Molecules
Recent Patents on Drug Delivery & Formulation Structure-Activity Relationships of Selective GABA Uptake Inhibitors
Current Topics in Medicinal Chemistry Bacterial Protein Toxins: Current and Potential Clinical Use
Current Medicinal Chemistry Anxiety: A Systematic Review of Neurobiology, Traditional Pharmaceuticals and Novel Alternatives from Medicinal Plants
CNS & Neurological Disorders - Drug Targets HIV-1 Induced CNS Dysfunction: Current Overview and Research Priorities
Current HIV Research Development of Polymeric Nanocarriers for Brain Targeted Delivery of Atorvastatin: A Quality-By-Design Approach
Drug Delivery Letters Cannabinoids
Current Drug Targets - CNS & Neurological Disorders Ring Finger Ubiquitin Protein Ligases and Their Implication to the Pathogenesis of Human Diseases
Current Pharmaceutical Design Nanotechnology in Neuroscience and its Perspective as Gene Carrier
Current Topics in Medicinal Chemistry TRPV1 Channel: A Potential Drug Target for Treating Epilepsy
Current Neuropharmacology Editorial [Hot Topic: Membrane Channels as Therapeutic Targets (Executive Editor: Jean-Claude Herve)]
Current Pharmaceutical Design Multifaceted Individualities in Pharmacological Treatments of Obesity
Current Clinical Pharmacology Cross-Cultural Comparison of Mild Cognitive Impairment between China and USA
Current Alzheimer Research Designed Multiple Ligands: Basic Research vs Clinical Outcomes
Current Medicinal Chemistry MG17, A Novel Triazole Derivative Abrogated Neuroinflammation and Related Neurodegenerative Symptoms in Rodents
Current Molecular Pharmacology Raf Inhibitors as Therapeutic Agents Against Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Editorial:Cannabis: Neurological Correlates in Abuse and Medical Use
CNS & Neurological Disorders - Drug Targets Clinical Risk Management of Interactions Between Natural Products and Drugs
Current Drug Metabolism UCLA’s Molecular Screening Shared Resource: Enhancing Small Molecule Discovery with Functional Genomics and New Technology
Combinatorial Chemistry & High Throughput Screening